SCHEMBL24007684

SCHEMBL24007684

Cc1ccc(C)n1-c1cc(C(F)(F)C(F)(F)F)n([C@@H]2CCOC2)n1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
SPR P35270 1/20 0.32
FPR1 P21462 1/20 0.32
MAP3K12 Q12852 6/20 0.32
PIK3CD O00329 2/20 0.31
ABL1 P00519 2/20 0.31
EGFR P00533 2/20 0.31
HCK P08631 2/20 0.31
SRC P12931 2/20 0.31
KDR P35968 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CB P42338 2/20 0.31
MTOR P42345 2/20 0.31
PIK3CG P48736 2/20 0.31
EPHB4 P54760 2/20 0.31
PRKDC P78527 2/20 0.31
PI4KB Q9UBF8 2/20 0.31
PDE10A Q9Y233 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24007359 1.00 PDE1A (0.32) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL25746244 0.92 FPR1 (0.34) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL25746250 0.92 FPR1 (0.34) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24007027 0.86 CNR2 (0.35) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24007834 0.86 CNR2 (0.35) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24816272 0.82 MAP3K12 (0.34) PDE1APDE1BPDE1CSPRMAP3K12
SCHEMBL26008990 0.82 PDE1A (0.39) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24007242 0.81 BRD4 (0.38) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24008010 0.81 BRD4 (0.38) PDE1APDE1BPDE1CSPRFPR1
SCHEMBL24007605 0.79 PDE1A (0.34) PDE1APDE1BPDE1CSPRFPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B PDE1A 3423/4885PDE1B 3103/4885PDE1C 3917/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B PDE1A 3423/4885PDE1B 3103/4885PDE1C 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.